NCT07590167尚未招募1 期
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C in Healthy Adult Volunteers
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- •The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit
排除标准
- •Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- •Other exclusions applied
研究组 & 干预措施
Sequence A (RT)
Experimental
Period 1: Reference Drug(AD-231A, AD-231D and AD-231C), Period 2 : Test Drug(AD-231)
干预措施: AD-231 (Drug)
Sequence A (RT)
Experimental
Period 1: Reference Drug(AD-231A, AD-231D and AD-231C), Period 2 : Test Drug(AD-231)
干预措施: AD-231A, AD-231D and AD-231C (Drug)
Sequence B (TR)
Experimental
Period 1: Test Drug(AD-231), Period 2 : Reference Drug(AD-231A, AD-231D and AD-231C)
干预措施: AD-231 (Drug)
Sequence B (TR)
Experimental
Period 1: Test Drug(AD-231), Period 2 : Reference Drug(AD-231A, AD-231D and AD-231C)
干预措施: AD-231A, AD-231D and AD-231C (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231CHyperlipidemiaHypertensionNCT07312773Addpharma Inc.55
尚未招募
1 期
A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232Diabetes MellitusNCT07538466Addpharma Inc.50
尚未招募
1 期
A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsChronic Heart FailureNCT07476157Addpharma Inc.70
尚未招募
1 期
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322HypertensionNCT07312799Addpharma Inc.41
尚未招募
1 期
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy AdultsChronic Liver Disease (CLD)NCT07521241Addpharma Inc.52